North America Herpes Simplex Virus Treatment Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    North America  Herpes Simplex Virus Treatment Market Overview 
    3.1    North America Herpes Simplex Virus Treatment Market Historical Value (2017-2023) 
    3.2    North America Herpes Simplex Virus Treatment Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    North America  Herpes Simplex Virus Treatment Market Landscape*
    5.1    North America Herpes Simplex Virus Treatment: Developers Landscape
        5.1.1    Analysis by Year of Establishment
        5.1.2    Analysis by Company Size
        5.1.3    Analysis by Region
    5.2    North America Herpes Simplex Virus Treatment: Product Landscape
        5.2.1    Analysis by Type    
        5.2.2    Analysis by Drug Type
6    North America Herpes Simplex Virus Treatment Market Dynamics
    6.1    Market Drivers and Constraints
    6.2    SWOT Analysis
        6.2.1    Strengths
        6.2.2    Weaknesses
        6.2.3    Opportunities
        6.2.4    Threats
    6.3    PESTEL Analysis 
        6.3.1    Political 
        6.3.2    Economic 
        6.3.3    Social 
        6.3.4    Technological 
        6.3.5    Legal 
        6.3.6    Environment
    6.4    Porter’s Five Forces Model
        6.4.1    Bargaining Power of Suppliers
        6.4.2    Bargaining Power of Buyers
        6.4.3    Threat of New Entrants
        6.4.4    Threat of Substitutes
        6.4.5    Degree of Rivalry
    6.5    Key Demand Indicators 
    6.6    Key Price Indicators
    6.7    Industry Events, Initiatives, and Trends  
    6.8    Value Chain Analysis
7    North America Herpes Simplex Virus Treatment Market Segmentation (2017-2032)
    7.1    North America Herpes Simplex Virus Treatment Market (2017-2032) by Type
        7.1.1    Market Overview
        7.1.2    Herpes Simples Virus-1 Infection
        7.1.3    Herpes Simplex Virus-2 Infection
        7.1.4    Others
    7.2    North America Herpes Simplex Virus Treatment Market (2017-2032) by Drug Type
        7.2.1    Market Overview
        7.2.2    Acyclovir
        7.2.3    Valacyclovir
        7.2.4    Famciclovir
        7.2.5    Others
    7.3    North America Herpes Simplex Virus Treatment Market (2017-2032) by Route of Administration
        7.3.1    Market Overview
        7.3.2    Oral
        7.3.3    Parenteral
        7.3.4    Topical
    7.4    North America Herpes Simplex Virus Treatment Market (2017-2032) by Country
        7.4.1    Market Overview
        7.4.2    United States
        7.4.3    Canada
8    United States  Herpes Simplex Virus Treatment Market (2017-2032)
    8.1    United States Herpes Simplex Virus Treatment Market (2017-2032) by Type
        8.1.1    Market Overview    
        8.1.2    Herpes Simples Virus-1 Infection
        8.1.3    Herpes Simplex Virus-2 Infection
        8.1.4    Others
    8.2    United States Herpes Simplex Virus Treatment Market (2017-2032) by Drug Type
        8.2.1    Market Overview
        8.2.2    Acyclovir
        8.2.3    Valacyclovir
        8.2.4    Famciclovir
        8.2.5    Others 
    8.3    United States Herpes Simplex Virus Treatment Market (2017-2032) by Route of Administration
        8.3.1    Market Overview
        8.3.2    Oral
        8.3.3    Parenteral
        8.3.4    Topical 
9    Canada Herpes Simplex Virus Treatment Market (2017-2032)
    9.1    Canada Herpes Simplex Virus Treatment Market (2017-2032) by Type
        9.1.1    Market Overview    
        9.1.2    Herpes Simples Virus-1 Infection
        9.1.3    Herpes Simplex Virus-2 Infection
        9.1.4    Others
    9.2    Canada Herpes Simplex Virus Treatment Market (2017-2032) by Drug Type
        9.2.1    Market Overview
        9.2.2    Acyclovir
        9.2.3    Valacyclovir
        9.2.4    Famciclovir
        9.2.5    Others
    9.3    Canada Herpes Simplex Virus Treatment Market (2017-2032) by Route of Administration
        9.3.1    Market Overview
        9.3.2    Oral
        9.3.3    Parenteral
        9.3.4    Topical 
10    Regulatory Framework
    10.1     FDA
11    Clinical Trial Analysis
    11.1    Analysis by Trial Registration Year
    11.2    Analysis by Trial Status
    11.3    Analysis by Trial Phase
    11.4    Analysis by Therapeutic Area
    11.5    Analysis by Geography
12    Grant Analysis
    12.1    Analysis by Year
    12.2    Analysis by Amount Awarded
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Grant Product
    12.5    Analysis by Funding Institute
    12.6    Analysis by Departments
    12.7    Analysis by Recipient Organization
13    Funding and Investment Analysis
    13.1     Analysis by Funding Instances
    13.2     Analysis by Type of Funding
    13.3     Analysis by Funding Amount
    13.4     Analysis by Leading Players
    13.5     Analysis by Leading Investors
    13.6     Analysis by Geography
14    Strategic Initiative
    14.1     Analysis by Partnership Instances
    14.2     Analysis by Type of Partnership
    14.3     Analysis by Leading Players
    14.4     Analysis by Geography
15    Supplier Landscape
    15.1     Market Share Analysis, By Region (Top 5 Companies)
        15.1.1    Market Share Analysis: North America
    15.2    Roche Holding AG
        15.2.1    Financial Analysis
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications 
    15.3    AbbVie Inc.
        15.3.1    Financial Analysis
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Johnson & Johnson
        15.4.1    Financial Analysis
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    GlaxoSmithKline plc
        15.5.1    Financial Analysis
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    Sanofi 
        15.6.1    Financial Analysis
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Mylan N.V.
        15.7.1    Financial Analysis
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    Teva Pharmaceutical Industries Ltd.
        15.8.1    Financial Analysis
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Novartis AG
        15.9.1    Financial Analysis
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Merck & Co., Inc.
        15.10.1    Financial Analysis
        15.10.2    Product Portfolio
        15.10.3    Demographic
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications
    15.11    Pfizer Inc. 
        15.11.1    Financial Analysis
        15.11.2    Product Portfolio
        15.11.3    Demographic Reach and Achievements
        15.11.4    Mergers and Acquisitions
        15.11.5    Certifications
16    North America Herpes Simplex Virus Treatment Market – Distribution Model (Additional Insight)
    16.1     Overview 
    16.2     Potential Distributors 
    16.3     Key Parameters for Distribution Partner Assessment 
17    Key Opinion Leaders (KOL) Insights (Additional Insight)
18    Payment Methods (Additional Insight)
    18.1     Government Funded
    18.2     Private Insurance
    18.3     Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.